LICENSE AGREEMENT

Nektar Therapeutics Inc – Bristol-Myers Squibb

BIOTECH GATE
BUSINESS DEVELOPMENT DATABASE

GENERAL INFORMATION

Deal date:	February 2018	Orphan status: Exclusivity:	Yes No
Type of agreement:	Joint Venture Licensing - product / compound	**Type of collaboration:**	Co-development, Co-marketing
Licensor:	Nektar Therapeutics Inc	**Licensee:**	Bristol-Myers Squibb

Agreement description:

Under the agreement, Nektar and Bristol-Myers Squibb (BMS) will jointly develop and commercialize NKTR-214, an IL-2 based CD122-biased agonist, in combination with BMS's Opdivo® (nivolumab) and Opdivo® plus Yervoy® (ipilimumab), and other compounds in more than 20 indications across 9 tumor types, as well as potential combinations with other anti-cancer agents from either of the respective companies and/or third parties.

Territory including	Worldwide	
Sources:	Contract	Download PDF
	Press release	Download PDF View in Browser

COMPOUND INFORMATION

Compound Name: NKTR-214 with Opdivo® (nivolumab) and Opdivo® plus Yervoy® (ipilimumab)

Compound details:

NKTR-214, a CD122-biased agonist, is an investigational immuno-stimulatory therapy designed to selectively expand cancer-fighting T cells and natural killer (NK) cells directly in the tumor micro-environment and increase PD-1 expression on those immune cells. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system to help restore anti-tumor immune response. Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity.

DISEASE INFORMATION

Main indication:	Neoplasms / cancer / oncology
Sub indication:	Melanoma and other skin cancers
Clinical Phase:	Phase I/II
Main indication:	Genitourinary system / Urology
Sub indication:	Other disorders of kidney and ureter
Clinical Phase:	Phase I/II
Main indication:	Neoplasms / cancer / oncology
Sub indication:	Non-small cell lung cancer
Clinical Phase:	Phase I/II
Main indication:	Neoplasms / cancer / oncology
Sub indication:	Bladder cancer
Clinical Phase:	Phase I/II
Main indication:	Neoplasms / cancer / oncology
Sub indication:	Breast cancer triple negative
Clinical Phase:	Phase I/II

MILESTONES & ROYALITIES

Deal size:	USD 2,780.00 million
Upfront payments:	USD 1,000.00 million
Upfront remarks:	Nektar will receive non-refundable upfront cash payment of USD 1,000 million

Regulatory milestone amount:

Total regulatory milestone amount:	USD 1,430.00 million

Sales milestone amount received:

Total sales milestone amount:	USD 350.00 million

Total milestone amount:	USD 1,780.00 million
Milestone remarks:	Nektar is eligible to receive additional cash payments of a total of up to USD 1430 M upon achievement of certain development and regulatory milestones.